FMC Secures Regulatory Approval for Keenali Herbicide in Peru
Werte in diesem Artikel
FMC Corporation FMC has received regulatory approvals for its Keenali herbicide, powered by Dodhylex active, in Peru. With this approval, FMC’s first active ingredient and commercial product has received global registration for this breakthrough herbicide technology. Dodhylex active is the first and only herbicide to be classified as a Group 28 herbicide by the Herbicide Resistance Action Committee and the Weed Science Society of America.This marks a huge step in the field of agricultural innovation and scientific leadership, FMC noted. Continuous research on the use of Dodhylex is being conducted to discover new benefits in additional crops, including corn, soybean, sugarcane and sunflower to combat resistant weeds. With its proven performance in matters of crop safety and broad utility in Japonica and Indica rice, Keenali, with the new mode of action, is now set to offer Peruvian rice growers an effective solution for managing yield-reducing and resistant grass weeds, including key grass weeds. This approval has made 10% of more than 4.5 million planted hectares of rice across Latin America accessible to FMC. Keenali herbicide is anticipated to be commercially available in Peru in August. FMC awaits approval for Dodhylex active in other countries of Latin America. It has also submitted regulatory applications to India, Japan, Malaysia, South Korea, Taiwan and the United States for Keenali. FMC remains committed to innovation and a disciplined approach to advancing new molecules that help combat resistance and support food security for a growing population.FMC stock has lost 34.5% over the past year compared with the industry’s 10.6% decline.Image Source: Zacks Investment ResearchFMC’s Zacks Rank and Key PicksFMC currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the Basic Materials space are Carpenter Technology Corporation CRS, DRDGOLD Limited DRD and Idaho Strategic Resources, Inc. IDR. While CRS sports a Zacks Rank #1 (Strong Buy) at present, DRD and IDR carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for Carpenter Technology’s current fiscal-year earnings is pegged at $6.95 per share. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 15.7%. CRS’ shares have soared 116.9% in the past year.The Zacks Consensus Estimate for DRD’s current-year earnings is pegged at $1.06 per share, indicating a 29.3% year-over-year rise. Its shares have soared 102.4% in the past year.The Zacks Consensus Estimate for IDR’s 2025 earnings is pegged at 78 cents per share, indicating a rise of 16.4% from year-ago levels. IDR’s earnings beat the consensus estimate in three of the trailing four quarters while missing once, with the average surprise being roughly 77.5%. Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Carpenter Technology Corporation (CRS): Free Stock Analysis Report FMC Corporation (FMC): Free Stock Analysis Report DRDGOLD Limited (DRD): Free Stock Analysis Report Idaho Strategic Resources, Inc. (IDR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: FMC und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf FMC
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf FMC
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Fresenius Medical Care (FMC) St.
Analysen zu Fresenius Medical Care (FMC) St.
Datum | Rating | Analyst | |
---|---|---|---|
23.04.2025 | Fresenius Medical Care (FMC) St Neutral | UBS AG | |
23.04.2025 | Fresenius Medical Care (FMC) St Buy | Goldman Sachs Group Inc. | |
22.04.2025 | Fresenius Medical Care (FMC) St Hold | Deutsche Bank AG | |
22.04.2025 | Fresenius Medical Care (FMC) St Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
22.04.2025 | Fresenius Medical Care (FMC) St Equal Weight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
23.04.2025 | Fresenius Medical Care (FMC) St Buy | Goldman Sachs Group Inc. | |
22.04.2025 | Fresenius Medical Care (FMC) St Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
12.03.2025 | Fresenius Medical Care (FMC) St Buy | Goldman Sachs Group Inc. | |
27.02.2025 | Fresenius Medical Care (FMC) St Kaufen | DZ BANK | |
25.02.2025 | Fresenius Medical Care (FMC) St Buy | Goldman Sachs Group Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
23.04.2025 | Fresenius Medical Care (FMC) St Neutral | UBS AG | |
22.04.2025 | Fresenius Medical Care (FMC) St Hold | Deutsche Bank AG | |
22.04.2025 | Fresenius Medical Care (FMC) St Equal Weight | Barclays Capital | |
16.04.2025 | Fresenius Medical Care (FMC) St Market-Perform | Bernstein Research | |
04.03.2025 | Fresenius Medical Care (FMC) St Market-Perform | Bernstein Research |
Datum | Rating | Analyst | |
---|---|---|---|
17.04.2025 | Fresenius Medical Care (FMC) St Underweight | JP Morgan Chase & Co. | |
21.03.2025 | Fresenius Medical Care (FMC) St Underperform | Jefferies & Company Inc. | |
04.03.2025 | Fresenius Medical Care (FMC) St Underperform | Jefferies & Company Inc. | |
26.02.2025 | Fresenius Medical Care (FMC) St Underweight | JP Morgan Chase & Co. | |
25.02.2025 | Fresenius Medical Care (FMC) St Underperform | Jefferies & Company Inc. |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Fresenius Medical Care (FMC) St. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen